Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

By Shuai Xia, Yun Zhu, Meiqin Liu, Qiaoshuai Lan, W. Xu, Yanling Wu, T. Ying, Shuwen Liu, Zhènglì Shí, Shibo Jiang and 1 more. Cellular & Molecular Immunology, 2020

636 citations recorded by the source corpus.

Very recently, a novel coronavirus, 2019-nCoV, emerged in Wuhan, China and then quickly spread worldwide, resulting in >17,388 confirmed cases and 361 deaths as of 3 February 2020, thus calling for the development of safe and effective therapeutics and prophylatics. Similar to severe acute respiratory syndrome (SARS)-CoV, 2019nCoV belongs to lineage B betacoronavirus, and it has the ability to utilize human angiotensin-converting enzyme 2 (ACE2) as a receptor to infect human cells. SARS-CoV spike (S) protein S2 subunit plays a key role in mediating virus fusion with and entry into the host cell, in which the heptad repeat 1 (HR1) and heptad repeat 2 (HR2) can interact to form six-helical bundle (6-HB), thereby bringing viral and cellular membranes in close proximity for fusion. Using S-HR1 as a target, we have previously designed and developed several potent fusion inhibitors against SARS-CoV (e.g., SARS-HR2P) and Middle East respiratory syndrome (MERS)-CoV (e.g., MERS-HR2P). However, it is unclear whether 2019-nCoV also possesses a similar fusion and entry mechanism as that of SARS-CoV and MERS-CoV, and if so, whether a 2019-nCoV S-HR1 can also serve as an important target for the development of 2019-nCoV fusion/entry inhibitors. Through amino acid (aa) sequence alignment with SARS-CoV and 2019-nCoV S protein, we located the functional domain in 2019-nCoV S protein, including N-terminal domain (aa14–305), receptor-binding domain (aa319–541), and receptor-binding motif (aa437–508) in S1 subunit (aa14–685) and fusion peptide (aa788–806), HR1 (aa912–984), HR2 (aa1163–1213), transmembrane domain (aa1214–1237) and cytoplasm domain (aa1238–1273) in S2 subunit (aa686–1273) (Fig. 1a). In the post-fusion hairpin conformation of the SARS-CoV or MERS-CoV S protein, the HR2 domain forms both rigid helix and flexible loop to interact with HR1 domain (Fig. 1b). There are many strong interactions between HR1 and HR2 domains inside the helical region, which is thus designated “fusion core region” (HR1core and HR2core regions, respectively). According to the sequence alignment, the 2019-nCoV and SARS-CoV S2 subunits are highly conserved, with 92.6% and 100% overall identity in HR1 and HR2 domains, respectively. However, inside the HR1core region, 8 of the 21 residues show mutation (~38% difference). This is significantly different from the HR1core region of previously identified SARS-like viruses, such as WIV1, Rs3367, and RsSHC014, which are 100% identical to that of SARS-CoV (Fig. 1b). These novel point mutations in 2019-nCoV S2 subunit may change the interaction pattern between HR1 and HR2 domains in the post-fusion core, thus affecting the 6-HB formation. Based on our previous experience, we have now designed HR1and HR2-derived peptides, designated 2019nCoV-HR1P (aa924–965) and 2019-nCoV-HR2P (aa1168–1203), respectively (Fig. 1c), and explored their biological characteristics. Since the 2019-nCoV and SARS-CoV S-HR2 sequences are 100% identical, 2019-nCoV-HR2P may act as a fusion inhibitor in much the same way as our reported SARS-CoV fusion inhibitor, SARS-HR2P. Under native electrophoresis as described before, 2019-nCoV-HR2P, which carries negative charges, moved down to a lower gel position, while 2019-nCoV-HR1P, which carries positive charges, moved up and off the gel (Fig. 1d) in a manner similar to SARS-CoV-HR1P in native-polyacrylamide gel electrophoresis (PAGE) assay. Notably, in the 2019-nCoV-HR1P/2019nCoV-HR2P mixture, new bands emerged at the upper part in the native-PAGE gel in a 2019-nCoV-HR1P dose-dependent manner, indicating that 2019-nCoV-HR2P could interact with 2019-nCoV-HR1P to form a complex, possibly 6-HB. We then assessed the secondary structures of 2019-nCoV-HR1P, 2019-nCoV-HR2P, and 2019-nCoV-HR1P/2019-nCoV-HR2P complex, using circular dichroism as previously described. While 2019-nCoV-HR1P alone and 2019-nCoV-HR2P alone exhibited low helicity (<30%), the 2019-nCoV-HR1P/2019-nCoV-HR2P complex exhibited the characteristic helicity of 6-HB, with minimum values at 208 and 222 nm and helicity of 84.4% (Fig. 1e). Moreover, the 2019-nCoV-HR1P/2019-nCoV-HR2P complex showed good thermal stability with Tm of 66.2 C (Fig. 1f). These results confirm, for the first time, that 2019-nCoV HR1 and HR2 regions are able to interact with each other to form 6HB and suggest that 2019-nCoV-HR2P may inhibit 2019-nCoV fusion with and entry into the target cell, as we showed before with SARS-CoV, MERS-CoV, and other human CoVs. To confirm this hypothesis, we herein developed a 2019-nCoV Smediated cell–cell fusion assay as previously described. Using this assay, we demonstrated that 2019-nCoV-HR2P exhibited potent fusion-inhibitory activity with a half maximal inhibitory concentration (IC50) of 0.18 μM (Fig. 1g), indicating that the 2019-nCoV HR1 region could serve as an ideal target site. On the other hand, 2019-nCoV-HR1P exhibited no significant inhibitory effect at concentrations up to 40 μM, consistent with other coronavirus HR1-derived peptides, such as SARS-HR1P and MERS-HR1P. We previously reported that the HR1 region in various coronaviruses is a conserved target site, and based on that evidence, we designed a pan-coronavirus fusion inhibitor, denoted as EK1. Compared with 2019-nCoV-HR2P, EK1 shows

Subfields: Genetics, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/2558ce5de7986f26d3016480b07e34c18c3c2a18

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

  1. L. Du

Citations in the corpus